Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.03.006
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2015
Authors
Publisher
Elsevier BV